Patents by Inventor Thomas Storz
Thomas Storz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230128639Abstract: The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds as sGC stimulators and their synthetic precursors.Type: ApplicationFiled: September 28, 2022Publication date: April 27, 2023Inventor: Thomas Storz
-
Publication number: 20230095799Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.Type: ApplicationFiled: September 28, 2022Publication date: March 30, 2023Inventors: Kwame Wiredu Nti-Addae, Leena Kumari Prasad, Thomas Storz
-
Patent number: 11466014Abstract: The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds of Formula IA: as sGC stimulators. The method comprises reacting the amidrazone compound represented by Formula IIA: or a salt thereof, with a carboxylic acid, an activated ester, a thioester, an acid halide, a thioacyl halide, or an acid anhydride in the presence of a base.Type: GrantFiled: March 7, 2019Date of Patent: October 11, 2022Assignee: Cyclerion Therapeutics, Inc.Inventor: Thomas Storz
-
Patent number: 11466015Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, depicted below as a compound of Formula (I): which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: March 7, 2019Date of Patent: October 11, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: Kwame W. Nti-Addae, Leena Kumari Prasad, Thomas Storz
-
Publication number: 20210115050Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.Type: ApplicationFiled: March 7, 2019Publication date: April 22, 2021Inventors: Kwame W. Nti-Addae, Leena Kumari Prasad, Thomas Storz
-
Publication number: 20210032254Abstract: The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds as sGC stimulators and their synthetic precursors.Type: ApplicationFiled: March 7, 2019Publication date: February 4, 2021Inventor: Thomas Storz
-
Patent number: 8288351Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 16, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8278280Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: GrantFiled: April 8, 2008Date of Patent: October 2, 2012Assignee: Amgen Inc.Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, Jr., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Patent number: 8247556Abstract: The invention encompasses a method for preparing 6-susbtituted-7-aza-indoles.Type: GrantFiled: October 20, 2006Date of Patent: August 21, 2012Assignee: Amgen Inc.Inventor: Thomas Storz
-
Patent number: 8183293Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.Type: GrantFiled: December 18, 2008Date of Patent: May 22, 2012Assignee: Amgen Inc.Inventors: Mark Grillo, An-Rong Li, Jiwen Liu, Julio C. Medina, Yongli Su, Yingcai Wang, Janan Jona, Alan Allgeier, Jacqueline Milne, Jerry Murry, Joseph F. Payack, Thomas Storz
-
Publication number: 20090275659Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.Type: ApplicationFiled: December 18, 2008Publication date: November 5, 2009Applicant: Amgen Inc.Inventors: Mark Grillo, An-Rong Li, Jiwen Liu, Julio C. Medina, Yongli Su, Yingcai Wang, Janan Jona, Alan Allgeier, Jacqueline Milne, Jerry Murry, Joseph F. Payack, Thomas Storz
-
Publication number: 20090137483Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: ApplicationFiled: April 8, 2008Publication date: May 28, 2009Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, JR., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Publication number: 20090137452Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: ApplicationFiled: April 8, 2008Publication date: May 28, 2009Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, JR., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Publication number: 20090048149Abstract: The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.Type: ApplicationFiled: April 9, 2008Publication date: February 19, 2009Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, JR., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
-
Publication number: 20070185171Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: October 20, 2006Publication date: August 9, 2007Inventors: Julie Germain, Benny Askew, David Bauer, Deborah Choquette, Lucian Dipietro, Russell Graceffa, Jean-Christophe Harmange, Qi Huang, Joseph Kim, Daniel La, Aiwen Li, Nobuko Nishimura, Rana Nomak, Vinod Patel, Michele Potashman, Babak Riahi, Thomas Storz, Simon Van Der Plas, Kevin Yang, Chester Yuan
-
Publication number: 20050215470Abstract: The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.Type: ApplicationFiled: October 21, 2004Publication date: September 29, 2005Inventors: Gordon Ng, Yue-Sheng Li, Colin Gegg, Benny Askew, Thomas Storz, Yuelie Lu, Derin D'Amico
-
Patent number: 6909003Abstract: The invention relates to a process for the manufacture of a compound of formula or a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the element represents —CH2—CH2— or —CH?CH— and R represents a cyclic radical.Type: GrantFiled: May 2, 2003Date of Patent: June 21, 2005Assignee: Novartis AGInventor: Thomas Storz
-
Patent number: 6670379Abstract: Compounds of formula (I) in free or salt form, where Ar1 is phenyl substituted by one or more halogen atoms, Ar2 is phenyl or naphthyl which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-alkoxycarbonyl, R1 is hydrogen or C1-C8-alkyl optionally substituted by hydroxy, C1-C8-alkoxy, acyloxy, N(R2)R3, halogen, carboxy, C1-C8-alkoxycarbonyl, —CON(R4)R5 or by a monovalent cyclic organic group, R2 and R3 are each independently hydrogen or C1-C8-alkyl, or R2 is hydrogen and R3 is acyl or —SO2R6, or R2 and R3 together with the nitrogen atom to which they are attached denote a 5 or 6-membered heterocyclic group, R4 and R5 are each independently hydrogen or C1-C8-alkyl, or R4 and R5 together with the nitrogen atom to which they are attached denote a 5 or 6-membered heterocyclic group, R6 is C1-C8-alkyl, C1-C8-haloalkyl, or phenyl optionally substituted by C1-C8-alkyl, and n is 1,Type: GrantFiled: April 17, 2003Date of Patent: December 30, 2003Assignee: Novartis AGInventors: Trevor John Howe, Gurdip Bhalay, Darren Mark Le Grand, Thomas Storz
-
Publication number: 20030233001Abstract: The invention relates to a process for the manufacture of a compound of formula 1Type: ApplicationFiled: May 2, 2003Publication date: December 18, 2003Inventor: Thomas Storz
-
Publication number: 20030176460Abstract: Compounds of formula (I) in free or salt form, where Ar1 is phenyl substituted by one or more halogen atoms, Ar2 is phenyl or naphthyl which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-alkoxycarbonyl, R1 is hydrogen or C1-C8-alkyl optionally substituted by hydroxy, C1-C8-alkoxy, acyloxy, N(R2)R3, halogen, carboxy, C1-C8-alkoxycarbonyl, —CON(R4)R5 or by a monovalent cyclic organic group, R2 and R3 are each independently hydrogen or C1-C8-alkyl, or R2 is hydrogen and R3 is acyl or —SO2R4 and R5 are each independently with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R4 and R5 are each independently hydrogen or C1-C8-alkyl, or R4 and R5 together with the nitrogen atom to which they are attached denote a 5-6-membered heterocyclic group, R6 is C1-C8-alkyl, C1-C8-haloalkyl, or phenyl optionally substituted by C1-C8-alkyl, and n is 1, 2, 3, or 4,Type: ApplicationFiled: April 17, 2003Publication date: September 18, 2003Inventors: Trevor John Howe, Gurdip Bhalay, Darren Mark Le Grand, Thomas Storz